Compare OII & AAPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OII | AAPG |
|---|---|---|
| Founded | 1964 | 2009 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.6B |
| IPO Year | N/A | 2025 |
| Metric | OII | AAPG |
|---|---|---|
| Price | $29.77 | $25.30 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $25.00 | ★ $48.50 |
| AVG Volume (30 Days) | ★ 1.0M | 3.6K |
| Earning Date | 02-18-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 73.60 | N/A |
| EPS | ★ 2.29 | N/A |
| Revenue | ★ $2,829,032,000.00 | $54,524,554.00 |
| Revenue This Year | $5.97 | N/A |
| Revenue Next Year | $0.85 | $368.64 |
| P/E Ratio | $13.27 | ★ N/A |
| Revenue Growth | ★ 8.71 | N/A |
| 52 Week Low | $15.46 | $17.09 |
| 52 Week High | $31.44 | $48.45 |
| Indicator | OII | AAPG |
|---|---|---|
| Relative Strength Index (RSI) | 62.86 | 33.57 |
| Support Level | $29.03 | $25.52 |
| Resistance Level | $31.44 | $26.30 |
| Average True Range (ATR) | 1.11 | 0.57 |
| MACD | 0.25 | -0.12 |
| Stochastic Oscillator | 68.89 | 0.00 |
Oceaneering International Inc is a provider of engineered services and products and robotic solutions to the offshore energy, defense, aerospace, manufacturing, and entertainment industries. A majority of its products are produced for the offshore oil and gas market. The company's business segments are Integrity Management and Digital Solutions, Subsea Robotics, Manufactured Products, Offshore Projects Group, and Aerospace and Defense Technologies. Maximum revenue is generated from its Subsea Robotics segment, which provides remotely operated vehicles (ROVs) for drill support and vessel-based services, underwater surveys, tooling, and other activities. Geographically, the company derives its key revenue from the United States, followed by Africa, Norway, Brazil, and other regions.
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies. The company's geographical segments include the United States and Mainland China.